Beijing Tong Ren Tang Chinese Medicine Company Limited (TONGRENTANGCM) will hold its 2026 Annual General Meeting (AGM) on 10 June 2026 at 3 Dai King Street, Tai Po Industrial Estate, Hong Kong, starting at 10:30 a.m.

Key proposals to be tabled as ordinary resolutions include:

• 2025 Financial Statements: Shareholders will vote on the adoption of the audited consolidated financial statements, the directors’ report and the independent auditor’s report for the year ended 31 December 2025.

• Board Composition: Re-election of Executive Director Mr Wang Chi and Independent Non-executive Directors Mr Tsang Yok Sing, Jasper and Mr Chan Ngai Chi. The board will be authorised to determine directors’ remuneration.

• Dividend Distribution: A final dividend of HK$0.37 per share and a special dividend of HK$0.03 per share are proposed, representing a combined cash payout of HK$0.40 per share for FY 2025.

• Auditor Re-appointment: Ernst & Young is nominated for re-appointment as external auditor, with the board authorised to fix the auditor’s remuneration.

• Capital Mandates: – General mandate permitting the board to allot, issue, grant or otherwise deal with shares up to 20% of the company’s issued share capital (excluding treasury shares) as at the date of the AGM. – Share repurchase mandate of up to 10% of issued shares (excluding treasury shares). – Extension mandate allowing the volume of any shares repurchased to be added to the 20% issuance limit.

Key timetable:

• Shareholder voting eligibility: Register of members closed from 5 June 2026 to 10 June 2026 (both days inclusive); transfers must be lodged by 4:30 p.m. on 4 June 2026. • Dividend entitlement: Register closed from 16 June 2026 to 18 June 2026; transfers must be lodged by 4:30 p.m. on 15 June 2026.

The board is currently composed of Executive Directors Yan Han (Chairman), Yue Zheng (Vice Chairman) and Wang Chi; Non-executive Director Feng Li; and Independent Non-executive Directors Tsang Yok Sing, Jasper, Xu Hong Xi and Chan Ngai Chi.